Related Experiment Video

Updated: Jun 29, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway

Ngai Na Co1, Wing Pui Tsang, Timothy W L Wong

  • 1Department of Biochemistry, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong Special Administrative Region, People's Republic of China.

Molecular Cancer Therapeutics
|October 15, 2008
PubMed

Insights

AF1q, a cancer-linked factor, regulates apoptosis and drug resistance. This study shows AF1q enhances doxorubicin-induced apoptosis by activating the BAD pathway, offering new insights into cancer treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • AF1q is an oncogenic factor implicated in various cancers, including leukemia, thyroid tumors, and breast cancer metastasis.
  • AF1q expression was found to be downregulated in doxorubicin-resistant human squamous carcinoma A431 cells.

Purpose of the Study:

  • To investigate the role of AF1q in regulating apoptosis and drug resistance.
  • To elucidate the molecular mechanisms by which AF1q influences apoptosis, particularly in response to chemotherapy.

Main Methods:

  • AF1q knockdown and overexpression in A431, HepG2, and HL60 cell lines.
  • Assessment of apoptosis induction by various agents (doxorubicin, Taxol, radiation, interferons).
  • Analysis of BAD protein levels, mitochondrial membrane potential, cytochrome c release, and caspase activation.

Main Results:

  • Knockdown of AF1q reduced doxorubicin-induced apoptosis, while overexpression enhanced it.
  • AF1q increased mRNA and protein levels of the proapoptotic protein BAD.
  • AF1q promoted mitochondrial depolarization, cytochrome c release, and caspase activation, indicating activation of the intrinsic apoptotic pathway.

Conclusions:

  • AF1q enhances doxorubicin-induced apoptosis through the BAD-mediated apoptotic pathway.
  • AF1q plays a critical role in regulating apoptosis and chemoresistance, presenting a potential therapeutic target.

More Related Videos

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...